PRMT5/MEP50 AS A CRITICAL EPIGENETIC REGULATOR AND THERAPEUTIC TARGET FOR THERAPY-INDUCED NEUROENDOCRINE PROSTATE CANCER

$1,081,246FY2022Defense Health AgencyDOD

Purdue University, West Lafayette IN

Investigators